Efruxifermin
Sponsors
Akero Therapeutics Inc., Akero Therapeutics, Inc
Conditions
FibrosisMASH - Metabolic Dysfunction-Associated SteatohepatitisMASH With FibrosisMetabolic Dysfunction-Associated Steatohepatitis (MASH)NAFLD/MASLDNASH - Nonalcoholic SteatohepatitisNASH With FibrosisNASH/MASH
Phase 2
Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating The Safety And Efficacy Of Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic
Dysfunction-Associated Steatohepatitis (MASH) And Fibrosis
RecruitingCTIS2023-505141-48-00
Start: 2024-03-07Target: 244Updated: 2026-01-22
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Active, not recruitingNCT06161571
Start: 2023-11-10End: 2026-06-19Target: 700Updated: 2026-04-30
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
RecruitingNCT06215716
Start: 2023-12-01End: 2033-02-01Target: 1650Updated: 2026-08-07
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
RecruitingNCT06528314
Start: 2024-09-04End: 2030-03-01Target: 2150Updated: 2026-09-08
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)
RecruitingCTIS2024-512895-36-00
Start: 2024-11-25Target: 170Updated: 2025-12-04